Licensing

Our specialist healthcare team, with backgrounds in the life sciences, understand the complexities of valuations and deal structures that are unique to licensing deals in pharma and biotech and are with our clients every step of the way.

We support clients with:

- In-licensing
- Out-licensing
- Drug licensing
- Facility licensing

Our Latest Deals

Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received a significant investment from
Nov 2021
has made an investment in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Jun 2021
has acquired a drug product manufacturing facility from
Jun 2021
has been acquired by
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with

Results. Great people creating great outcomes, together.

Latest Insights

Insights
19th January 2022

Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!

The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]

Reports
10th November 2021

CDMO Market Update

We are pleased to share with you the CDMO Market Update – November 2021, where we analyse global M&A activity and public market valuations in the CDMO sector. H1 2021 was an exceptional start to the year with 48 deals in total in the CDMO sector, almost reaching the total annual transactions in the previous four […]

Reports
3rd November 2021

Marketing Services: Global M&A and Public Company Performance Q3 2021

We are pleased to share with you the Q3 2021 Marketing Services Sector Review, where we analyse global M&A activity and public market performance in the marketing services sector. The M&A market for Marketing Services remains buoyant and dynamic with Q1-Q3 2021 deal volume up by 30% on the comparative period at 569 and 441 […]